<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03626376</url>
  </required_header>
  <id_info>
    <org_study_id>17-01134</org_study_id>
    <nct_id>NCT03626376</nct_id>
  </id_info>
  <brief_title>Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis</brief_title>
  <official_title>A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized clinical trial looking to determine the role of&#xD;
      prophylactic treatment with topical corticosteroids in preventing recurrences in patients&#xD;
      with a history of infectious epithelial keratitis, stromal keratitis,endotheliitis, or&#xD;
      iridocyclitis. Patients will be enrolled to one of two treatment arms: Control arm: oral&#xD;
      acyclovir 400 mg BID OR valacyclovir 500 mg daily or Study arm: oral acyclovir 400 mg BID OR&#xD;
      valacyclovir 500 mg qdaily + topical corticosteroid eye drops.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">March 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of time to first recurrence</measure>
    <time_frame>24 Months</time_frame>
    <description>Kaplan-Meier curves will be plotted by treatment arm (overall and by site) and 95% confidence intervals for the difference between the time to first recurrences will be estimated. Results will also be plotted by site to provide descriptive summaries of the results.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Herpes Simplex Virus Keratitis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>suppressive antiviral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral acyclovir or oral valacyclovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily</intervention_name>
    <description>Treatment used in standard of care</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops</intervention_name>
    <description>Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject capable of giving informed consent and if not, an acceptable surrogate capable&#xD;
             of giving informed consent on behalf of the subject.&#xD;
&#xD;
          -  Diagnosed with a history of herpetic eye disease&#xD;
&#xD;
          -  Three or more episodes of HSV keratitis based on medical record documentation of&#xD;
             episodes with infectious epithelial keratitis, immune stromal keratitis with or&#xD;
             without epithelial ulceration, endothelitis, or iridocyclitis.&#xD;
&#xD;
          -  Prior history of HSV keratitis based on medical record documentation of episode of&#xD;
             infectious epithelial keratitis, immune stromal keratitis with or without epithelial&#xD;
             ulceration, endothelitis, or iridocyclitis and corneal scarring in the central 4mm&#xD;
             zone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons who are pregnant or nursing or intend to become pregnant or nurse in the next&#xD;
             one year.&#xD;
&#xD;
          -  Allergy to acyclovir, fluoromethalone, loteprednol, prednisolone acetate, prednisolone&#xD;
             sodium phosphate, or any components of the formulations.&#xD;
&#xD;
          -  Persons who are incarcerated.&#xD;
&#xD;
          -  Unable to give informed consent or have an acceptable surrogate capable of giving&#xD;
             informed consent on behalf of the subject.&#xD;
&#xD;
          -  Persons with systemic medical problems who do not agree to have continued medical&#xD;
             follow-up.&#xD;
&#xD;
          -  History of topical corticosteroids to the eyelids or ocular surface of the involved&#xD;
             eye within the prior 30 days prior to enrollment.&#xD;
&#xD;
          -  Patients with 3 or more episodes of uveitis in the past 12 months.&#xD;
&#xD;
          -  History of keratoplasy or keratorefractive surgery of the involved eye.&#xD;
&#xD;
          -  History of open or closed angle glaucoma or ocular hypertension on gtts.&#xD;
&#xD;
          -  History of systemic steroid use within the prior 30 days.&#xD;
&#xD;
          -  Unable to comply with the study protocol or in the opinion of the investigator would&#xD;
             not be a candidate for participation.&#xD;
&#xD;
          -  Persons who are unable to instill gtts despite training/caregiver.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zena Moore</last_name>
    <phone>+1 929 455 5539</phone>
    <email>Zena.Moore@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Mach</last_name>
      <phone>929-455-5539</phone>
      <email>Stacy.Mach@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Leela Raju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Keratitis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

